WHO Essential Medicines Policies and Use in Developing and Transitional Countries: An Analysis of Reported Policy Implementation and Medicines Use Surveys

English version České info

Background:
Suboptimal medicine use is a global public health problem. For 35 years the World Health Organization (WHO) has promoted essential medicines policies to improve quality use of medicines (QUM), but evidence of their effectiveness is lacking, and uptake by countries remains low. Our objective was to determine whether WHO essential medicines policies are associated with better QUM.

Methods and Findings:
We compared results from independently conducted medicines use surveys in countries that did versus did not report implementation of WHO essential medicines policies. We extracted survey data on ten validated QUM indicators and 36 self-reported policy implementation variables from WHO databases for 2002–2008. We calculated the average difference (as percent) for the QUM indicators between countries reporting versus not reporting implementation of specific policies. Policies associated with positive effects were included in a regression of a composite QUM score on total numbers of implemented policies. Data were available for 56 countries. Twenty-seven policies were associated with better use of at least two percentage points. Eighteen policies were associated with significantly better use (unadjusted p<0.05), of which four were associated with positive differences of 10% or more: undergraduate training of doctors in standard treatment guidelines, undergraduate training of nurses in standard treatment guidelines, the ministry of health having a unit promoting rational use of medicines, and provision of essential medicines free at point of care to all patients. In regression analyses national wealth was positively associated with the composite QUM score and the number of policies reported as being implemented in that country. There was a positive correlation between the number of policies (out of the 27 policies with an effect size of 2% or more) that countries reported implementing and the composite QUM score (r = 0.39, 95% CI 0.14 to 0.59, p = 0.003). This correlation weakened but remained significant after inclusion of national wealth in multiple linear regression analyses. Multiple policies were more strongly associated with the QUM score in the 28 countries with gross national income per capita below the median value (US$2,333) (r = 0.43, 95% CI 0.06 to 0.69, p = 0.023) than in the 28 countries with values above the median (r = 0.22, 95% CI −0.15 to 0.56, p = 0.261). The main limitations of the study are the reliance on self-report of policy implementation and measures of medicine use from small surveys. While the data can be used to explore the association of essential medicines policies with medicine use, they cannot be used to compare or benchmark individual country performance.

Conclusions:
WHO essential medicines policies are associated with improved QUM, particularly in low-income countries.

Please see later in the article for the Editors' Summary

Vyšlo v časopise: WHO Essential Medicines Policies and Use in Developing and Transitional Countries: An Analysis of Reported Policy Implementation and Medicines Use Surveys. PLoS Med 11(9): e32767. doi:10.1371/journal.pmed.1001724
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001724

Souhrn

Conclusions:
WHO essential medicines policies are associated with improved QUM, particularly in low-income countries.

Please see later in the article for the Editors' Summary

Zdroje

1. HollowayKA (2011) Combating inappropriate use of medicines. Expert Rev Clin Pharmacol 4: 335–348.

2. Holloway KA, van Dijk L, World Health Organization (2011) The world medicines situation, third edition. WHOb/EMP/MIE/2011.2.2. Geneva: World Health Organization. Available: http://www.who.int/medicines/areas/policy/world_medicines_situation/en/index.html. Accessed 5 July 2013.

3. World Health Organization (2009) Medicines use in primary care in developing and transitional countries: fact book summarizing results from studies reported between 1990 and 2006. WHO/EMP/MAR/2009.3. Geneva: World Health Organization.

4. LivermoreDM (2003) Bacterial resistance: origins, epidemiology, and impact. Clin Infect Dis 36 (Suppl 1)S11–S23.

5. HarbarthS, SamoreMH (2005) Antimicrobial resistance determinants and future control. Emerg Infect Dis 11: 794–801.

6. GoossensH (2009) Antibiotic consumption and link to resistance. Clin Microbiol Infect 15 (Suppl 3)12–15.

7. PirmohamedM, JamesS, MeakinS, GreenC, ScottAK, et al. (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ 329: 15–19.

8. HowardRL, AveryAJ, SlavenburgS, RoyalS, PipeG, et al. (2006) Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol 63: 136–147.

9. HitchenL (2006) Adverse drug reactions result in 250 000 UK admissions a year. BMJ 332: 1109.

10. World Health Organization (1985) The rational use of drugs: report of the conference of experts. Geneva: World Health Organization.

11. World Health Organization (2002) Promoting rational use of medicines: core components. WHO Policy Perspectives of Medicines, No. 5. Geneva: World Health Organization.

12. World Health Organization (2006) Using indicators to measure country pharmaceutical situations: fact book on WHO level I and level II monitoring indicators. WHO/TCM/2006.2. Geneva: World Health Organization.

13. World Health Organization (2010) Country pharmaceutical situations: fact book on WHO level 1 indicators 2007. WHO/EMP/MPC/2010.1. Geneva World Health Organization.

14. HollowayKA, IvanovskaV, WagnerAK, Vialle-ValentinC, Ross-DegnanD (2013) Have we improved use of medicines in developing and transitional countries and do we know how to? Two decades of evidence. Trop Med Int Health 18: 656–664.

15. Holloway KA, Ivanovska V, Wagner AK, Vialle-Valentin C, Ross-Degnan D (2014) Prescribing for acute childhood infections in developing and transitional countries, 1990–2009. Paediatr Int Child Health. E-pub ahead of print. doi:10.1179/2046905514Y.0000000115

16. MölstadS, ErntellM, HanbergerH, MelanderE, NormanC, et al. (2008) Sustained reduction of antibiotic use and low bacterial resistance: 10 year follow-up of the Swedish STRAMA programme. Lancet Infect Dis 8: 125–132.

17. HuttnerB, GoossensH, VerheijT, HarbathS (2009) CHAMP consortium (2009) Characteristics and outcomes of public campaigns with the aim to improve outpatient antibiotic use in high income countries. Lancet Infect Dis 10: 17–31.

18. SabuncuE, DavidJ, Bernède-BauduinC, PépinS, LeroyM, et al. (2009) Significant reduction of antibiotic use in the community after a nationwide campaign in France, 2002–2007. PLoS Med 6: e1000084.

19. RatanawijitrasinS, SoumeraiSB, WeerasuriyaK (2001) Do national medicinal drug policies and essential drug programs improve drug use? A review of experiences in developing countries. Soc Sci Med 53: 831–844.

20. World Health Organization (1993) How to investigate drug use in health facilities: selected drug use indicators. WHO/DAP/93.1. Geneva: World Health Organization.

21. GoveS (1997) Integrated management of childhood illness by outpatient health workers: technical basis and overview. The WHO Working Group on Guidelines for Integrated Management of the Sick Child. Bull World Health Organ 75 (Suppl 1)7–24.

22. World Health Organization (2007) WHO operational package for assessing, monitoring and evaluating country pharmaceutical situations: guide for coordinators and data collectors. WHO/TCM/2007.2. Geneva: World Health Organization.

23. World Health Organization (2006) Expert meeting on pharmaceutical indicators, monitoring and assessment. Geneva: World Health Organization.

24. World Health Organization (2011) Development of country profiles and monitoring of the pharmaceutical situation in countries. Available: http://www.who.int/medicines/areas/coordination/coordination_assessment/en/. Accessed 15 May 2014.

25. RoweAK, de SavignyD, LanataCF, VictoraCG (2005) How can we achieve and maintain high-quality performance of health workers in low resource settings? Lancet 366: 1026–1035.

26. FranckeAL, SmitMC, De VeerAJE, MistiaenP (2008) Factors influencing the implementation of clinical guidelines for health care professionals: a meta-review. BMC Med Inform Decis Mak 8: 38.

27. SketrisIS, IngramEML, LummisHL (2009) Strategic opportunities for effective optimal prescribing and medication management. Can J Clin Pharmacol 16: e103–e125.

28. Jaffer B (2007) National approach of promote rational use of medicines: the Omani experience. Available: http://www.who.int/drugresistance/OmanDRDUforWHAMeetingGeneva.pdf. Accessed 5 July 2013.

29. BavestrelloL, CabelloA, CasanovaD (2002) Impact of regulatory measures in the trends of community consumption of antibiotics in Chile. Rev Med Chil 130: 1265–1272.

30. ChenW, TangS, SunJ, Ross-DegnanD, WagnerA (2010) Availability and use of essential medicines in China: manufacturing, supply and prescribing in Shandong and Gansu provinces. BMC Health Serv Res 10: 211 doi:10.1186/1472-6963-10-211

31. TrapB, HansenEH, HogerzeilHV (2002) Prescription habits of dispensing and non-dispensing doctors in Zimbabwe. Health Policy Plan 17: 288–295.

32. TrapB, HansenEH (2002) Treatment of upper respiratory tract infections—a comparative study of dispensing and non-dispensing doctors. J Clin Pharm Ther 27: 289–299.

33. ParkS, SoumeraiSB, AdamsAS, FinkelsteinJA, JangS, et al. (2005) Antibiotic use following a Korean national policy to prohibit medication dispensing by physicians. Health Policy Plan 20: 302–309.

34. World Health Organization (2004) Drug Promotion: what we know, what we have yet to learn—reviews of materials in the WHO/HAI Database on Drug Promotion. EDM Research Series, No. 32, WHO/EDM/PAR/2004.3. Geneva: World Health Organization.

35. SaundersP, Kamal-YanniM (2012) Urgent need for WHO's reform to prioritise core functions. Lancet 379: 1878.

36. SaundersP, Kamal-YanniM (2013) Action to preserve WHO's core medicines-related roles—1 year on. Lancet 381: 293–294.